ArticleCancers2019
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies.Frontiers in immunology · 2023Pooled it
- The renaissance ofFrontiers in immunology · 2026Review
- AttenuatedFrontiers in immunology · 2026Review
- Cytolysin A is an intracellularly induced and secreted cytotoxin of typhoidal Salmonella.Nature communications · 2024Article
- A tellurium-based small compound ameliorates tumor metastasis by downregulating heparanase expression.Journal of Cancer · 2024Article
- Article
- Harnessing microbial antigens as cancer antigens: a promising avenue for cancer immunotherapy.Frontiers in immunology · 2024Review
- Arbutin overcomes tumor immune tolerance by inhibiting tumor programmed cell death-ligand 1 expression.International journal of medical sciences · 2024Article
- Converting bacteria into autologous tumor vaccineActa pharmaceutica Sinica. B · 2023Article
- Review
- Review
- Bacteria in cancer therapy: A new generation of weapons.Cancer medicine · 2022Review
- Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.Journal of hematology & oncology · 2022Review
- Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer.Frontiers in immunology · 2022Article
- IL22RA1/JAK/STAT Signaling Acts As a Cancer Target Through Pan-Cancer Analysis.Frontiers in immunology · 2022Article
- Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model.Current research in immunology · 2022Article
- The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors.Nanomaterials (Basel, Switzerland) · 2021Review
- Highlights of Immunomodulation inBiomedicines · 2021Review
- Integration ofCancers · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy is becoming a popular treatment modality in combat against cancer, one of the world's leading health problems. While tumor cells influence host immunity via expressing immune inhibitory signaling proteins, some bacteria possess immunomodulatory activities that counter the symptoms of tumors. The accumulation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.